Medical oncologist Isabelle Ray-Coquard issued a global call for physicians to help shape future ovarian cancer care through a new international questionnaire.
Every physician managing or participating in the care of ovarian cancer patients should contribute to the survey, Oncodaily reported.
“Ovarian cancer patients need our support … every physicians managing, participating to, these patients should participate to be sure the questionnaire will be representative of all parts of the world! Please help us,” Isabelle Ray-Coquard, medical oncologist at Léon Bérard Center, stated on LinkedIn.
The effort forms a central part of the Lancet Commission on Ovarian Cancer, an international forum spanning screening, prevention, biology, therapeutics, survivorship, and patient experience. The initiative runs across a three-year timeline to produce a comprehensive report guiding future clinical policy.
- Clinicians treating ovarian cancer globally are urged to complete a specialized questionnaire to ensure care strategies reflect diverse international populations.
- The initiative operates under the Lancet Commission on Ovarian Cancer, directing a three-year project to shape future screening and therapeutic standards.
- Patient representation and clinical insights from worldwide practices remain vital for building a truly comprehensive global health policy report.
Ana Oaknin, head of the gynecological cancer program at Hospital Universitario Puerta del Hierro, stressed the importance of wide participation across medical communities.
“Your voice matters! The Lancet Commission on Ovarian Cancer is an international forum of experts on ovarian cancer screening, prevention, biology, therapeutics, survivorship and patient experience. Over 3 years, it will produce a Commission report to guide future policy. A physician survey is a key part of this effort. Take part in the Lancet Commission on Ovarian Cancer Survey and help shape the future of ovarian cancer care. Every contribution counts,” Oaknin told Oncodaily – Oncology News, Insights, Stories.
The commission brings together international experts to evaluate the entire continuum of the disease, from early detection methods to long-term survivorship. By capturing diverse physician experiences through the questionnaire, researchers aim to address disparities in global treatment access and clinical outcomes.
Isabelle Ray-Coquard, MD, PhD, of Centre Léon Bérard in Lyon, France, led the phase III PAOLA-1 trial published in The New England Journal of Medicine in 2020, demonstrating a progression-free survival benefit from adding olaparib to bevacizumab maintenance in advanced ovarian cancer. She obtained her medical degree in 1997 and a PhD from Université Claude Bernard in 2003, also holding Master’s degrees in medical economics and statistics.
From 2008 to 2013, she chaired the gynecologic clinical trials group for the French National Cancer Institute (INCA) and currently directs the national rare ovarian cancer observatory (ovaire-rare.org). She has served as President of the GINECO group and chaired the rare cancer working group of the Gynecologic Cancer InterGroup (GCIG) from 2009 to 2016.
| Commission Focus Area | Scope of Evaluation | Project Timeline |
|---|---|---|
| Screening & Prevention | Early detection protocols and risk mitigation | 3 Years |
| Therapeutics & Biology | Treatment pathways and disease mechanisms | 3 Years |
| Survivorship & Experience | Long-term patient quality of life | 3 Years |
The survey remains open to clinicians worldwide as part of the broader international effort to close existing survival gaps in gynecological oncology.
- The Lancet Commission on Ovarian Cancer. International Expert Forum and Global Survey Initiatives.
- Oncodaily. Isabelle Ray-Coquard: A Global Call to Help Shape Ovarian Cancer Care.